Nuvilex Inc (NVLX) 0.2900 $NVLX
Nuvilex Nears Crucial Quality of Life Study in Malignant Ascites Associated with Pancreatic and Other Abdominal Cancers
ACCESSWIRE - Wed Jul 23, 8:01AM CDT
New York, NY / ACCESSWIRE / July 23, 2014 / Nuvilex, Inc. (OTCQB: NVLX) will begin preclinical studies in early August with its Contract Research Organization (CRO) Translational Drug Development (TD2) to study the first of 4 symptoms associated with pancreatic cancer and other abdominal cancers. In what is essentially the biggest step in Nuvilex's history to date, the company will enter the clinic under its own brand for the first time ever, and it will do so with the highly respected oncology CRO, TD2 and its Chief Development Officer, Dr. Daniel Von Hoff. In the studies, Nuvilex and TD2 will determine what effect the company's pancreatic cancer treatment will have on these symptoms.
Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
ACCESSWIRE - Tue Jul 22, 8:32AM CDT
WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component of the index, also fell over 5% last week.
Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide
GlobeNewswire - Thu Jul 17, 9:25AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of a veterinary Phase I/II clinical trial in dogs with mammary tumors who were treated with Cell-in-a-Box cellulose-based live cell encapsulation plus the widely used anticancer drug cyclophosphamide (Cytoxan). These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Nuvilex Provides Shareholder Update on Milestone Accomplishments
GlobeNewswire - Mon Jul 14, 8:01AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today issued the following shareholder update letter from Kenneth L. Waggoner, CEO and President.
Nuvilex Analyst Report: Potentially Revolutionary Technology Positions Biopharmaceutical Firm as a Cancer Market Competitor - Fundamentals Need to Catch up With Expectations by BrokerBank Securities, Inc.
PR Newswire - Mon Jul 14, 6:45AM CDT
Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biopharmaceutical competitor is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box®. This unique technology is intended for use as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
Nuvilex Scheduled to Begin Preclinical Studies in Early August
GlobeNewswire - Wed Jul 09, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that all preparations for the commencement of its preclinical studies to determine the effectiveness of Nuvilex's pancreatic cancer treatment in slowing down the accumulation of ascites fluid have been completed. As previously announced, Translational Drug Development, LLC (TD2) will conduct the study. Ascites fluid accumulates in the abdomen and is usually associated with the development of advanced pancreatic and other abdominal cancers.
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
Marketwire - Mon Jul 07, 8:01AM CDT
Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO International Convention in San Diego. One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex's plans for treating diabetes. This, of course, begs the question -- is Nuvilex in line for a partnership to bring its diabetes treatment to market?
Nuvilex Executives Attend 2014 BIO International Convention
GlobeNewswire - Tue Jul 01, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Chief Executive Officer and President Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree attended the 2014 BIO International Convention held June 23-26, 2014, in San Diego, California. The event allowed the CEO and COO to spend valuable time with Cell-in-a-Box co-developers, Drs. Walter Gunzburg and Brian Salmons, Clinical Network Services of Australia who will conduct Nuvilex's Phase 2b clinical trial in pancreatic cancer and with a representative of the Juvenile Diabetes Research Foundation about Nuvilex's plans for treating diabetes.
Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
Marketwire - Fri Jun 20, 8:01AM CDT
Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational Drug Development (TD2) will be conducting the preclinical studies and clinical trials that will follow to study the Maryland biotech's pancreatic cancer treatment and its ability to relieve symptoms associated with the deadly cancer, Nuvilex entered into a high profile opportunity.
Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers
Marketwire - Thu Jun 12, 8:02AM CDT
Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech firm. With preclinical studies set to begin any day now at Translational Drug Development (TD2), this is the first time the pancreatic cancer treatment that combines the live-cell encapsulation technology Cell-in-a-Box(R) with the anticancer drug ifosfamide will enter the clinic under the Nuvilex name.
Maple Leaf Green World Ahead of the Game with Production Scale, Know-How
ACCESSWIRE - Thu Jun 05, 8:31AM CDT
Whitefish, MT / June 5, 2014 / Maple Leaf Green World's (CVE: MGW) (OTC: MPEFF) recent signature of an agreement to lease Woodmere Nursery's 7-acre Telkwa, B.C. greenhouse facility (with an option to purchase the entire facility) has catapulted the company to the forefront of the rapidly emerging Canadian medical cannabis (MMJ) space.
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
Marketwire - Thu Jun 05, 2:04AM CDT
Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's pancreatic cancer treatment in an interview with Stock Market Media Group, a research and content development investment relations firm, while the two were attending the American Society of Clinical Oncology (ASCO) conference in Chicago from Friday May 30 to Tuesday June 3.
Hemp Based Products Grow in Popularity as R&D Studies Reveal Progress - NEWC Announces Results for Recent Market Study
PR Newswire - Tue Jun 03, 7:50AM CDT
Cannabis companies making progress by forging ahead with product developments, Hemp based product studies and form business partnerships as the industry expands: New Colombia Resources, Inc. (OTC: NEWC), Cannabis Science, Inc. (OTC: CBIS), Tranzbyte Corporation (OTC: ERBB), Nuvilex, Inc. (OTC: NVLX) and Hemp, Inc. (OTC: HEMP)
Nuvilex to Present at the LD MICRO Invitational Conference on June 4, 2014
GlobeNewswire - Fri May 30, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Kenneth L. Waggoner, CEO and President, will present at the fourth annual LD MICRO Invitational Conference at the Luxe Hotel in Los Angeles, California on Wednesday, June 4th, 2014 at 4:00pm PDT. Nuvilex and approximately one hundred other companies will be presenting and conducting private meetings with potential investors over the course of the day on June 4.
Nuvilex Enters Into an At the Market Banking Agreement With Chardan Capital Markets
GlobeNewswire - Thu May 29, 9:02AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into an "At the Market" banking agreement with Chardan Capital Markets, LLC under which Nuvilex may seek to raise up to a total of $50,000,000 depending upon market conditions and at the discretion of Nuvilex. In the banking agreement, Chardan Capital Markets will act as the exclusive placement agent for Nuvilex. The funds will be used for: (i) late-phase clinical trials in pancreatic cancer with Clinical Network Services (CNS) in Australia; (ii) preclinical studies and clinical trials with Translational Drug Development (TD2) to address the symptoms of pancreatic cancer to be conducted in the U.S.; and (iii) further testing and research for diabetes in Europe.
Medical Marijuana Industry Looks to Stabilize as Cannabis Operations Forge Ahead - Company Continues Expansion with New Colorado Office as Regional Hub for Surveillance and Security Solutions
PR Newswire - Thu May 29, 8:01AM CDT
Medical marijuana advancers execute internal and external plans in order to boost performance as the industry seeks to balance out: DirectView Holdings, Inc. (OTC: DIRV), Creative Edge Nutrition, Inc. (OTC: FITX), Medical Marijuana, Inc. (OTC: MJNA), Nuvilex, Inc. (OTC: NVLX) and Terra Tech Corp. (OTC: TRTC)
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer
Nuvilex to Present at the Third Annual Marcum MicroCap Conference
GlobeNewswire - Wed May 28, 1:21PM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its CEO and President, Kenneth L. Waggoner, will be a featured presenter at the Third Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. The Company's presentation by Mr. Waggoner is scheduled to begin at 3:30 p.m. EDT.
Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
PR Newswire - Thu May 22, 10:30AM CDT
Cannabis Industry making strides in developing new patents, therapy solutions and diversified products for medical patients: Cannabis Science, Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), New Colombia Resources, Inc. (OTC: NEWC), GW Pharmaceuticals plc (NASDAQ: GWPH), and Nuvilex, Inc. (OTC: NVLX).
Nuvilex Nears Crucial Quality of Life Study in Malignant Ascites Associated with Pancreatic and Other Abdominal Cancers
ACCESSWIRE - Wed Jul 23, 8:01AM CDT
New York, NY / ACCESSWIRE / July 23, 2014 / Nuvilex, Inc. (OTCQB: NVLX) will begin preclinical studies in early August with its Contract Research Organization (CRO) Translational Drug Development (TD2) to study the first of 4 symptoms associated with pancreatic cancer and other abdominal cancers. In what is essentially the biggest step in Nuvilex's history to date, the company will enter the clinic under its own brand for the first time ever, and it will do so with the highly respected oncology CRO, TD2 and its Chief Development Officer, Dr. Daniel Von Hoff. In the studies, Nuvilex and TD2 will determine what effect the company's pancreatic cancer treatment will have on these symptoms.
Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
ACCESSWIRE - Tue Jul 22, 8:32AM CDT
WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component of the index, also fell over 5% last week.
Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide
GlobeNewswire - Thu Jul 17, 9:25AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of a veterinary Phase I/II clinical trial in dogs with mammary tumors who were treated with Cell-in-a-Box cellulose-based live cell encapsulation plus the widely used anticancer drug cyclophosphamide (Cytoxan). These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Nuvilex Provides Shareholder Update on Milestone Accomplishments
GlobeNewswire - Mon Jul 14, 8:01AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today issued the following shareholder update letter from Kenneth L. Waggoner, CEO and President.
Nuvilex Analyst Report: Potentially Revolutionary Technology Positions Biopharmaceutical Firm as a Cancer Market Competitor - Fundamentals Need to Catch up With Expectations by BrokerBank Securities, Inc.
PR Newswire - Mon Jul 14, 6:45AM CDT
Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biopharmaceutical competitor is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box®. This unique technology is intended for use as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
Nuvilex Scheduled to Begin Preclinical Studies in Early August
GlobeNewswire - Wed Jul 09, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that all preparations for the commencement of its preclinical studies to determine the effectiveness of Nuvilex's pancreatic cancer treatment in slowing down the accumulation of ascites fluid have been completed. As previously announced, Translational Drug Development, LLC (TD2) will conduct the study. Ascites fluid accumulates in the abdomen and is usually associated with the development of advanced pancreatic and other abdominal cancers.
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
Marketwire - Mon Jul 07, 8:01AM CDT
Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO International Convention in San Diego. One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex's plans for treating diabetes. This, of course, begs the question -- is Nuvilex in line for a partnership to bring its diabetes treatment to market?
Nuvilex Executives Attend 2014 BIO International Convention
GlobeNewswire - Tue Jul 01, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Chief Executive Officer and President Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree attended the 2014 BIO International Convention held June 23-26, 2014, in San Diego, California. The event allowed the CEO and COO to spend valuable time with Cell-in-a-Box co-developers, Drs. Walter Gunzburg and Brian Salmons, Clinical Network Services of Australia who will conduct Nuvilex's Phase 2b clinical trial in pancreatic cancer and with a representative of the Juvenile Diabetes Research Foundation about Nuvilex's plans for treating diabetes.
Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
Marketwire - Fri Jun 20, 8:01AM CDT
Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational Drug Development (TD2) will be conducting the preclinical studies and clinical trials that will follow to study the Maryland biotech's pancreatic cancer treatment and its ability to relieve symptoms associated with the deadly cancer, Nuvilex entered into a high profile opportunity.
Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers
Marketwire - Thu Jun 12, 8:02AM CDT
Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech firm. With preclinical studies set to begin any day now at Translational Drug Development (TD2), this is the first time the pancreatic cancer treatment that combines the live-cell encapsulation technology Cell-in-a-Box(R) with the anticancer drug ifosfamide will enter the clinic under the Nuvilex name.
Maple Leaf Green World Ahead of the Game with Production Scale, Know-How
ACCESSWIRE - Thu Jun 05, 8:31AM CDT
Whitefish, MT / June 5, 2014 / Maple Leaf Green World's (CVE: MGW) (OTC: MPEFF) recent signature of an agreement to lease Woodmere Nursery's 7-acre Telkwa, B.C. greenhouse facility (with an option to purchase the entire facility) has catapulted the company to the forefront of the rapidly emerging Canadian medical cannabis (MMJ) space.
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
Marketwire - Thu Jun 05, 2:04AM CDT
Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's pancreatic cancer treatment in an interview with Stock Market Media Group, a research and content development investment relations firm, while the two were attending the American Society of Clinical Oncology (ASCO) conference in Chicago from Friday May 30 to Tuesday June 3.
Hemp Based Products Grow in Popularity as R&D Studies Reveal Progress - NEWC Announces Results for Recent Market Study
PR Newswire - Tue Jun 03, 7:50AM CDT
Cannabis companies making progress by forging ahead with product developments, Hemp based product studies and form business partnerships as the industry expands: New Colombia Resources, Inc. (OTC: NEWC), Cannabis Science, Inc. (OTC: CBIS), Tranzbyte Corporation (OTC: ERBB), Nuvilex, Inc. (OTC: NVLX) and Hemp, Inc. (OTC: HEMP)
Nuvilex to Present at the LD MICRO Invitational Conference on June 4, 2014
GlobeNewswire - Fri May 30, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Kenneth L. Waggoner, CEO and President, will present at the fourth annual LD MICRO Invitational Conference at the Luxe Hotel in Los Angeles, California on Wednesday, June 4th, 2014 at 4:00pm PDT. Nuvilex and approximately one hundred other companies will be presenting and conducting private meetings with potential investors over the course of the day on June 4.
Nuvilex Enters Into an At the Market Banking Agreement With Chardan Capital Markets
GlobeNewswire - Thu May 29, 9:02AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into an "At the Market" banking agreement with Chardan Capital Markets, LLC under which Nuvilex may seek to raise up to a total of $50,000,000 depending upon market conditions and at the discretion of Nuvilex. In the banking agreement, Chardan Capital Markets will act as the exclusive placement agent for Nuvilex. The funds will be used for: (i) late-phase clinical trials in pancreatic cancer with Clinical Network Services (CNS) in Australia; (ii) preclinical studies and clinical trials with Translational Drug Development (TD2) to address the symptoms of pancreatic cancer to be conducted in the U.S.; and (iii) further testing and research for diabetes in Europe.
Medical Marijuana Industry Looks to Stabilize as Cannabis Operations Forge Ahead - Company Continues Expansion with New Colorado Office as Regional Hub for Surveillance and Security Solutions
PR Newswire - Thu May 29, 8:01AM CDT
Medical marijuana advancers execute internal and external plans in order to boost performance as the industry seeks to balance out: DirectView Holdings, Inc. (OTC: DIRV), Creative Edge Nutrition, Inc. (OTC: FITX), Medical Marijuana, Inc. (OTC: MJNA), Nuvilex, Inc. (OTC: NVLX) and Terra Tech Corp. (OTC: TRTC)
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer
Nuvilex to Present at the Third Annual Marcum MicroCap Conference
GlobeNewswire - Wed May 28, 1:21PM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its CEO and President, Kenneth L. Waggoner, will be a featured presenter at the Third Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. The Company's presentation by Mr. Waggoner is scheduled to begin at 3:30 p.m. EDT.
Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
PR Newswire - Thu May 22, 10:30AM CDT
Cannabis Industry making strides in developing new patents, therapy solutions and diversified products for medical patients: Cannabis Science, Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), New Colombia Resources, Inc. (OTC: NEWC), GW Pharmaceuticals plc (NASDAQ: GWPH), and Nuvilex, Inc. (OTC: NVLX).
